论文部分内容阅读
溶栓药物的靶向运输系统可提高溶栓药物的特异性和靶向性,减少溶栓药物全身用药所致的各种不良反应和临床并发症。血小板膜糖蛋白Ⅱb/Ⅲa受体的活化是血小板聚集的最终共同通道,在血栓形成中起到重要作用。RGD序列作为活化血小板膜糖蛋白Ⅱb/Ⅲa受体的特异性配体,具有抗血小板聚集作用和血栓靶向性。因此国内外学者运用RGD序列制备靶向溶栓药物,并对此类药物进行靶向溶栓研究。现就RGD靶向溶栓药物的研究进展做一综述。
Targeted delivery systems for thrombolytic agents increase the specificity and targeting of thrombolytic agents and reduce the variety of adverse reactions and clinical complications associated with systemic administration of thrombolytic agents. Platelet membrane glycoprotein Ⅱ b / Ⅲ a receptor activation is the ultimate common pathway of platelet aggregation, plays an important role in thrombosis. RGD sequence as a specific ligand for activated platelet membrane glycoprotein Ⅱ b / Ⅲ a receptor, with anti-platelet aggregation and thrombus targeting. Therefore, domestic and foreign scholars use RGD sequence preparation of targeted thrombolytic drugs, and targeted thrombolytic study of these drugs. The research progress of RGD targeting thrombolytic drugs is reviewed.